- Medicenna (MDNA) has priced its 13,333,334-unit marketed public offering at US$1.50 per unit
- The company intends to use the funds to further develop its product pipeline
- It expects the offering to close on or around August 11, 2022
- Medicenna is a clinical-stage immunotherapy company focused on fine-tuning the immune system to combat the most challenging diseases
- Medicenna Therapeutics (MDNA) is down by 41.85 per cent trading at $1.32 per share
Medicenna (MDNA) has priced its 13,333,334-unit marketed public offering at US$1.50 per unit.
Each unit is comprised of one common share and one common share purchase warrant.
Each warrant entitles the holder to purchase one common share priced at US$1.85 for 60 months following the date of closing.
It intends to use the net proceeds to fund the clinical development of MDNA11, the pre-clinical development of a BiSKIT candidate, as well as for working capital and general corporate purposes.
Guggenheim Securities is acting as sole book-running manager with Bloom Burton Securities acting as co-manager.
The company expects the offering to close on or around August 11, 2022.
Medicenna is a clinical-stage immunotherapy company focused on fine-tuning the immune system to combat the most challenging diseases, including a broad range of cancers.
Medicenna Therapeutics (MDNA) is down by 41.85 per cent trading at $1.32 per share as of 1:48 pm EST.
